COMMUNIQUÉS West-GlobeNewswire

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
05/02/2026
MELBOURNE, Australia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, [...]
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
05/02/2026
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and [...]
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
05/02/2026
The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029 The Pediatric Priority [...]
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
05/02/2026
– Live video webcast on Tuesday, February 10 th at 1:00 PM EST TAMPA, Fla. and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX ), an oncology biotechnology company pioneering next- [...]
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
05/02/2026
Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “ [...]
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
05/02/2026
Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics, Inc. , a biotech company harnessing [...]
Polaryx Therapeutics Welcomes New Members of the Board of Directors
05/02/2026
PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics , Inc. (Nasdaq: PLYX ) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease- [...]
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
05/02/2026
SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook: [...]
Chiesi Global Rare Diseases Reinforces Long-Term Commitment to the Rare Disease Community with Multiple Abstract Presentations at the 22nd Annual WORLDSymposium™
05/02/2026
-- Chiesi’s abstract presentations will focus on clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- These scientific contributions in lysosomal storage disorders (LSDs) [...]
ICU Medical Announces Time of Fourth Quarter 2025 Earnings Conference Call
05/02/2026
SAN CLEMENTE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter [...]
Alignment Healthcare to Announce Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call Thursday, Feb. 26, 2026
05/02/2026
ORANGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its fourth quarter and full-year 2025 financial results on Thursday, Feb. 26, 2026, after market close. Following [...]
Alumis to Participate in Upcoming February Investor Conferences
05/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today [...]
Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
05/02/2026
Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2 [...]
Basic Jane Advances Science-Led Cannabinoid Platform Focused on Senior Care and Scalable Product Formats
05/02/2026
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Basic Jane, a consumer product–focused subsidiary of Verda Bio, today highlighted its evolution from a mission-driven CBD brand into a scalable, partner-ready cannabinoid [...]
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
05/02/2026
Year-end report discusses combination therapy’s Mechanism of Action activating both innate and adaptive immune responses OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or [...]
Erasca to Present at Upcoming Conferences in February
05/02/2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
05/02/2026
Appointment Strengthens RenovoRx’s C-Suite Leadership to Support Commercial Growth of RenovoCath® MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a [...]
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
05/02/2026
– Live video webcast on Wednesday, February 11 th at 1:20 PM EST HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will [...]
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
05/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for [...]

Pages